$LNTH
Lantheus Holdings, Inc. Stock $lnth

$lnth Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000119312515366322 Filed on November 04, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q4
Revenue	$71.20M	$74.12M	$76.97M
YoY Change	-7.49%	-2.06%	7.39%
Cost Of Revenue	$37.82M	$40.42M	$44.21M
YoY Change	-14.45%	-8.23%	-28.45%
Gross Profit	$33.38M	$33.71M	$32.76M
YoY Change	1.89%	6.53%	231.59%
Gross Profit Margin	46.88%	45.47%	42.56%
Selling, General & Admin	$17.93M	$17.84M	$16.32M
YoY Change	9.87%	-7.89%	5.7%
% of Gross Profit	53.71%	52.93%	49.82%
Research & Development	$3.070M	$2.458M	$4.720M
YoY Change	-34.96%	-19.38%	-6.16%
% of Gross Profit	9.2%	7.29%	14.41%
Depreciation & Amortization	$3.000M	$1.900M	$3.440M
YoY Change	-12.79%	-13.64%	-0.86%
% of Gross Profit	8.99%	5.64%	10.5%
Operating Expenses	$20.99M	$20.30M	$21.03M
YoY Change	-0.19%	-9.46%	81.45%
Operating Profit	$12.39M	$13.41M	$11.73M
YoY Change	5.63%	45.41%	-786.02%
Interest Expense	-$7.860M	$7.100M	-$10.53M
YoY Change	-25.36%	-167.62%	-1.22%
% of Operating Profit	-63.43%	52.95%	-89.76%
Other Income/Expense, Net	$440.0K	-$183.0K	$590.0K
YoY Change	-25.42%	-141.5%	34.09%
Pretax Income	$4.970M	$6.125M	$1.800M
YoY Change	176.11%	-763.6%	-115.57%
Income Tax	$1.060M	$739.0K	$1.570M
% Of Pretax Income	21.33%	12.07%	87.22%
Net Earnings	$3.916M	$5.386M	$227.0K
YoY Change	1625.11%	-721.22%	-101.85%
Net Earnings / Revenue	5.5%	7.27%	0.29%
Basic Earnings Per Share	$0.13	$0.18
Diluted Earnings Per Share	$0.13	$0.18	$8.706K
COMMON SHARES
Basic Shares Outstanding	31.47M shares	30.36M shares
Diluted Shares Outstanding		30.76M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.60M	$21.90M	$19.70M
YoY Change	45.18%	-19.19%	5.91%
Cash & Equivalents	$28.60M	$21.92M	$19.74M
Short-Term Investments
Other Short-Term Assets	$3.851M	$5.210M	$4.374M
YoY Change	-11.96%	24.05%	41.1%
Inventory	$15.62M	$16.58M	$15.58M
Prepaid Expenses
Receivables	$37.29M	$39.72M	$41.54M
Other Receivables	$1.000M	$0.00	$2.000M
Total Short-Term Assets	$90.01M	$83.44M	$81.24M
YoY Change	10.8%	-6.67%	2.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$95.65M	$92.39M	$96.01M
YoY Change	-0.37%	-3.86%	-1.73%
Goodwill	$15.71M	$15.71M	$15.71M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.51M	$20.12M	$20.58M
YoY Change	-0.34%	-27.63%	-36.09%
Total Long-Term Assets	$152.4M	$152.7M	$161.9M
YoY Change	-5.89%	-10.49%	-11.08%
TOTAL ASSETS
Total Short-Term Assets	$90.01M	$83.44M	$81.24M
Total Long-Term Assets	$152.4M	$152.7M	$161.9M
Total Assets	$242.4M	$236.1M	$243.2M
YoY Change	-0.32%	-9.18%	-6.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.66M	$10.70M	$15.67M
YoY Change	-25.59%	-30.52%	-13.45%
Accrued Expenses	$18.50M	$20.00M	$24.90M
YoY Change	-25.7%	-43.02%	-2.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$8.000M
YoY Change	-100.0%	-100.0%	0.0%
Long-Term Debt Due	$3.650M	$3.650M	$0.00
YoY Change
Total Short-Term Liabilities	$35.52M	$34.32M	$48.53M
YoY Change	-26.8%	-42.42%	-12.72%
LONG-TERM LIABILITIES
Long-Term Debt	$349.9M	$350.4M	$392.9M
YoY Change	-10.95%	-12.23%	-1.54%
Other Long-Term Liabilities	$34.14M	$33.52M	$33.60M
YoY Change	1.62%	-16.21%	-20.2%
Total Long-Term Liabilities	$384.0M	$383.9M	$426.5M
YoY Change	-9.96%	-12.59%	-3.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$35.52M	$34.32M	$48.53M
Total Long-Term Liabilities	$384.0M	$383.9M	$426.5M
Total Liabilities	$427.7M	$426.3M	$482.4M
YoY Change	-11.35%	-14.54%	-2.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$359.2M	-$363.1M	-$344.4M
YoY Change	4.28%
Common Stock	$175.9M	$175.4M	$106.9M
YoY Change	64.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$106.0K
YoY Change
Treasury Stock Shares		0.000 shares	5.037K shares
Shareholders Equity	-$185.3M	-$190.1M	-$239.3M
YoY Change
Total Liabilities & Shareholders Equity	$242.4M	$236.1M	$243.2M
YoY Change	-0.32%	-9.18%	-6.94%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q4
OPERATING ACTIVITIES
Net Income	$3.916M	$5.386M	$227.0K
YoY Change	1625.11%	-721.22%	-101.85%
Depreciation, Depletion And Amortization	$3.000M	$1.900M	$3.440M
YoY Change	-12.79%	-13.64%	-0.86%
Cash From Operating Activities	$12.62M	$5.420M	-$3.880M
YoY Change	-425.26%	-73.59%	0.26%
INVESTING ACTIVITIES
Capital Expenditures	-$4.730M	-$2.310M	-$2.840M
YoY Change	66.55%	26.92%	118.46%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$4.730M	-$2.310M	-$2.830M
YoY Change	67.14%	44.38%	-1330.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.040M	-3.020M	-360.0K
YoY Change	188.89%	-58.8%	80.0%
NET CHANGE
Cash From Operating Activities	12.62M	5.420M	-3.880M
Cash From Investing Activities	-4.730M	-2.310M	-2.830M
Cash From Financing Activities	-1.040M	-3.020M	-360.0K
Net Change In Cash	6.850M	90.00K	-7.070M
YoY Change	-196.89%	-99.22%	84.11%
FREE CASH FLOW
Cash From Operating Activities	$12.62M	$5.420M	-$3.880M
Capital Expenditures	-$4.730M	-$2.310M	-$2.840M
Free Cash Flow	$17.35M	$7.730M	-$1.040M
YoY Change	-1768.27%	-65.4%	-59.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31472015	shares
CY2015Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	3650000
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10700000
CY2015Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	334000
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-363076000
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27127000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1321772	shares
CY2015Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.10
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30364501	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.03
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	871470	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30364501	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.01
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1275332	shares
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	175075000
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	526000
CY2015Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	8074000
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11152000
CY2015Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	970000
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	-190145000
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	350367000
CY2015Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	19968000
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33518000
CY2015Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1561000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	137933000
CY2015Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000
CY2015Q3	us-gaap	Liabilities Liabilities	426277000
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	236132000
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	303000
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	67533000
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	34318000
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2447000
CY2015Q3	us-gaap	Interest Payable Current InterestPayableCurrent	94000
CY2015Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4129000
CY2015Q3	lnth	Number Of Commercial Products NumberOfCommercialProducts	10	Item
CY2015Q3	lnth	Accrued Freight Costs Current AccruedFreightCostsCurrent	3199000
CY2015Q3	lnth	Accrued Rebates Discounts And Chargebacks Current AccruedRebatesDiscountsAndChargebacksCurrent	2292000
CY2015Q3	lnth	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	174000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-235517000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18578000
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21922000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2753000
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2015Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	5700000
CY2015Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7172000
CY2015Q3	lnth	Inventory Raw Materials Noncurrent InventoryRawMaterialsNoncurrent	1200000
CY2015Q3	lnth	Asset Retirement Obligation Liabilities Expected Present Value AssetRetirementObligationLiabilitiesExpectedPresentValue	26000000
CY2015Q3	lnth	Number Of Radiopharmacies Owned NumberOfRadiopharmaciesOwned	7	Item
CY2015Q3	lnth	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	17735000
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20120000
CY2015Q3	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	1981000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2015Q3	us-gaap	Assets Assets	236132000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3473000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	5276000
CY2015Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	1156000
CY2015Q3	us-gaap	Inventory Net InventoryNet	16579000
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39724000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1467000
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	92393000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	7634000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1886000
CY2015Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5278000
CY2015Q3	us-gaap	Assets Current AssetsCurrent	83435000
CY2015Q3	us-gaap	Other Assets Current OtherAssetsCurrent	5210000
CY2015Q3	us-gaap	Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset	4400000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	160422000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22489000
CY2015Q3	us-gaap	Goodwill Goodwill	15714000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1531110	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5037	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.57
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18075907	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	161693000
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18080944	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	106699000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	704000
CY2014Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	7435000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11198000
CY2014Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	978000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-239270000
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	392863000
CY2014Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	24863000
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33597000
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1508000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	134502000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15665000
CY2014Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	8000000
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	585000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-344414000
CY2014Q4	us-gaap	Liabilities Liabilities	482423000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	243153000
CY2014Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	400000000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	181000
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61432000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48528000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1630000
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4994000
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1788000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20578000
CY2014Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	2421000
CY2014Q4	us-gaap	Assets Assets	243153000
CY2014Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1156000
CY2014Q4	us-gaap	Inventory Net InventoryNet	15582000
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41540000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96014000
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7751000
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	106000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	81235000
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4374000
CY2014Q4	us-gaap	Impaired Assets To Be Disposed Of By Method Other Than Sale Carrying Value Of Asset ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset	7400000
	us-gaap	Share Based Compensation ShareBasedCompensation	782000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3979000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	27227000
CY2014Q4	us-gaap	Goodwill Goodwill	15714000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19739000
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6043000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27191000
CY2014Q4	lnth	Inventory Raw Materials Noncurrent InventoryRawMaterialsNoncurrent	1200000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4162000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-339000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	375000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1488000
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	5500000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	72000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-374000
CY2014Q4	lnth	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	16738000
CY2014Q4	lnth	Accrued Freight Costs Current AccruedFreightCostsCurrent	3069000
CY2014Q4	lnth	Accrued Rebates Discounts And Chargebacks Current AccruedRebatesDiscountsAndChargebacksCurrent	2164000
CY2014Q4	lnth	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	248000
CY2015Q2	lnth	Accrued Interest Paid AccruedInterestPaid	3300000
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	10900000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	15465000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18080496	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18080496	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.08
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-31704000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3788000
	us-gaap	Revenues Revenues	224631000
	us-gaap	Interest Paid InterestPaid	19692000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1758000
	us-gaap	Operating Income Loss OperatingIncomeLoss	27690000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-668000
	us-gaap	Gross Profit GrossProfit	92758000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-148000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2383000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1312000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-311000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	52000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5303000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4127000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	139000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8549000
	us-gaap	Operating Expenses OperatingExpenses	65068000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4848000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1936000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8958000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-30000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	227000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-132000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5915000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	Segment
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Inventory Write Down InventoryWriteDown	1529000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28883000
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	5500000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5700000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	131873000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2971000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14808000
	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	2319000
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	228000
	us-gaap	Depreciation Depreciation	6500000
	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	163000
	lnth	Public Offering Costs Incurred But Not Yet Paid PublicOfferingCostsIncurredButNotYetPaid	561000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>1. Business Overview</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Overview</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Holdings, a Delaware corporation, is the parent company of LMI, also a Delaware corporation.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company develops, manufactures, sells and distributes innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. The Company sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations and, in certain circumstances, wholesalers. The Company sells its products globally and has operations in the United States, Puerto Rico, Canada and Australia and distribution relationships in Europe, Asia Pacific and Latin America.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company’s portfolio of 10 commercial products is diversified across a range of imaging modalities. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the United States, is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">TechneLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Xenon Xe 133 Gas, or Xenon, is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name sestamibi, used with Single Photon Emission Computed Tomography, or SPECT, technology in myocardial perfusion imaging, or MPI, procedures that assess blood flow distribution to the heart.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Neurolite is an injectable, technetium-labeled imaging agent used with SPECT technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In the United States, the Company sells DEFINITY through its sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company’s radiopharmaceutical products are primarily distributed through commercial radiopharmacies owned or controlled by third parties. In Canada, Puerto Rico and Australia, the Company owns seven radiopharmacies and sells its own radiopharmaceuticals, as well as others, directly to end users. In Europe, Asia Pacific and Latin America, the Company utilizes distributor relationships to market, sell and distribute its products.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>Basis of Consolidation and Presentation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The financial statements have been prepared in United States dollars, in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The condensed consolidated financial statements include the accounts of Holdings and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s financial statements for interim periods in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The information included in this quarterly report should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes included in the Company’s Prospectus dated June 24, 2015 and filed with the SEC on June 26, 2015, or the Prospectus. The Company’s accounting policies are described in the “Notes to Consolidated Financial Statements” in the Prospectus and updated, as necessary, in this quarterly report. There were no changes to the Company’s accounting policies since December 31, 2014 except that the Company has adopted a new accounting policy as discussed further below. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>Recent Events</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> On June 25, 2015, in conjunction with its initial public offering, or IPO, the Company effected a corporate reorganization, whereby Lantheus MI Intermediate, Inc. (formerly the direct parent of LMI and the direct subsidiary of Holdings) was merged with and into Holdings, or the Merger.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On June 30, 2015, the Company completed an IPO of its common stock at a price to the public of $6.00 per share. The Company’s common stock is now traded on the NASDAQ Global Select Market (NASDAQ) under the symbol “LNTH”. The Company issued and sold 12,256,577 shares of common stock in the IPO, including 1,423,243 shares that were offered and sold pursuant to the underwriters’ exercise in full of its overallotment option. The IPO resulted in proceeds to the Company of approximately $67.2 million, after deducting $6.4 million in underwriting discounts, commissions and related expenses.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On June 30, 2015, the Company also entered into a $365.0 million senior secured term loan facility, or the Term Facility. The net proceeds of the Term Facility, together with the net proceeds from the IPO and the cash use of $10.9 million were used to repay in full the aggregate principal amount of LMI’s $400.0 million 9.750% Senior Notes due 2017, or the Notes, pay related premiums, interest and expenses and pay down the $8.0 million of outstanding borrowings under LMI’s $50.0 million revolving credit facility, or the Revolving Facility.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company currently relies on Jubilant HollisterStier, or JHS, as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company has additional ongoing technology transfer activities at JHS for its Cardiolite product supply, which is currently manufactured by a single manufacturer. In addition, the Company has ongoing technology transfer activities at Pharmalucence for the manufacture and supply of DEFINITY, and the Company believes it will file for U.S. Food and Drug Administration, or FDA, approval to manufacture DEFINITY at Pharmalucence in 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company’s ability to maintain and profitably renew these contracts and relationships with these key customers and group purchasing organizations is an important aspect of the Company’s strategy. The Company’s written supply agreements with a major customer relating to TechneLite, Xenon, Neurolite, Cardiolite and certain other products expired in accordance with contract terms on December 31, 2014. Extended discussions with this customer have not yet resulted in new written supply agreements. Consequently, the Company is currently accepting and fulfilling product orders with this customer on a purchase order basis.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> During 2013 and 2014, the Company has utilized its revolving line of credit as a source of liquidity from time to time. Borrowing capacity under the Revolving Facility is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves, or the Borrowing Base. If the Company is not successful in achieving its forecasted operating results, the Company’s accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company’s borrowing capacity. As of September 30, 2015, the aggregate Borrowing Base was approximately $46.2 million, which was reduced by the $8.8 million unfunded Standby Letter of Credit and $0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately $37.3 million. The Company’s new Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the revolving line of credit may affect the Company’s ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Based on the Company’s current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company’s liquidity requirements for at least the next twelve months.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities, accrued expenses and stock-based compensation. Actual results could materially differ from those estimates or assumptions.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>Stock Split</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In conjunction with the Merger, the Company effected a 0.355872-for-1 reverse stock split for its common stock. Upon consummation of the Merger, the par value of the common stock changed from $0.001 to $0.01. Accordingly, all references to share and per share information in the condensed consolidated financial statements have been adjusted to reflect the stock split and new par value for all periods presented.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>Debt Issuance Costs</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In April 2015, the Financial Accounting Standards Board, or the FASB, issued ASU No. 2015-03, “<i>Interest—Imputation of Interest (Topic 835): Simplifying the Presentation of Debt Issuance Costs</i>,” or ASU 2015-03. Under the new ASU, debt issuance costs related to a recognized debt liability will be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability. As a result, the Company’s balance sheet will reflect a reclassification of unamortized debt issuance costs from other long-term assets to long-term debt, net. ASU 2015-03 is effective for interim and annual periods beginning after December 15, 2015, and early adoption is permitted. The Company has adopted this standard effective as of June 30, 2015 and applied the changes retrospectively to the prior periods presented. Adoption of this standard has resulted in the reclassification of $6.4 million from other long-term assets to long-term debt, net on the balance sheet at December 31, 2014. Unamortized debt issuance costs of $5.7 million are recorded as a reduction to long-term debt, net on the condensed consolidated balance sheets at September 30, 2015.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In August 2015, FASB issued ASU No. 2015-15 “<i>Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line of Credit Arrangements,</i>” or ASU 2015-15. ASU 2015-15 indicates that the guidance in ASU 2015-03 did not address presentation or subsequent measurement of debt issuance costs related to line of credit arrangements. Given the absence of authoritative guidance within ASU 2015-03, the SEC staff has indicated that they would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the costs ratably over the term of the line of credit arrangement, regardless of whether there are any outstanding borrowings on the line of credit arrangement. The adoption of ASU 2015-15 did not have any effect on the Company’s financial position or results of operations.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	9136000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y1M6D
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.83
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001521036
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	One vote per share
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.11
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	LANTHEUS HOLDINGS, INC.
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22443257	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	281474	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	456150	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22443257	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.44
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.355872	pure
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	dei	Trading Symbol TradingSymbol	LNTH
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	19.25
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y1M6D
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	6258000
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-31599000
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	7000
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	97000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18662000
	us-gaap	Revenues Revenues	222260000
	us-gaap	Interest Paid InterestPaid	34275000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1524000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	563000
	us-gaap	Operating Income Loss OperatingIncomeLoss	30142000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2441000
	us-gaap	Gross Profit GrossProfit	102141000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	234000
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	400000000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-790000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-817000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1075000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-989000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	969000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-15528000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	8419000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19479000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	6297000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16751000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-817000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	81000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	940000
	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	9752000
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	8000000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2598000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1911000
	us-gaap	Share Based Compensation ShareBasedCompensation	1524000
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	6362000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	26934000
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	639000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2183000
	us-gaap	Operating Expenses OperatingExpenses	71999000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8419000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2041000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11292000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-85000
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	97000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-575000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3997000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33773000
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3561000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	360438000
	us-gaap	Inventory Write Down InventoryWriteDown	1073000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4500000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	120119000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	73539000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2765000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	16648000
	us-gaap	Depreciation Depreciation	9600000
	lnth	Financial Assurance In Form Of Surety Bond FinancialAssuranceInFormOfSuretyBond	28200000
	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	1216000
	lnth	Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriodWeightedAverageExercisePrice	21.33
	lnth	Share Based Compensation Arrangement By Share Based Payment Award Options Cancellations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationsInPeriod	34663	shares
	lnth	Financial Assurance In Form Of Letter Of Credit FinancialAssuranceInFormOfLetterOfCredit	8800000
	lnth	Amount Capitalized As Inventory AmountCapitalizedAsInventory	0
	lnth	Public Offering Costs Incurred But Not Yet Paid PublicOfferingCostsIncurredButNotYetPaid	104000
	lnth	Debt Instrument Covenant Consolidated Fixed Charge Coverage Ratio During Cash Dominion Period DebtInstrumentCovenantConsolidatedFixedChargeCoverageRatioDuringCashDominionPeriod	1	pure
	lnth	Percentage Of Greatest Amount Of Letter Of Credit Drawn PercentageOfGreatestAmountOfLetterOfCreditDrawn	1.05	pure
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1031000
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1236000
CY2014	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	6400000
CY2015Q3	us-gaap	Gross Profit GrossProfit	33705000
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-183000
CY2015Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-628000
CY2014	lnth	Amount Capitalized As Inventory AmountCapitalizedAsInventory	0
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18080968	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18080968	shares
CY2014Q3	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-10585000
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-867000
CY2014Q3	us-gaap	Revenues Revenues	75682000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	9221000
CY2014Q3	us-gaap	Gross Profit GrossProfit	31638000
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	441000
CY2014Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	82000
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1538000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-923000
CY2014Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-671000
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-56000
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	247000
CY2014Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8327000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	22417000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3049000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11041000
CY2014Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1900000
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	44044000
CY2014Q3	us-gaap	Depreciation Depreciation	2200000
CY2014Q3	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	359000
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.18
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30761771	shares
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	112344	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30359516	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.35
CY2015Q3	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-7100000
CY2015Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	6000
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5386000
CY2015Q3	us-gaap	Revenues Revenues	74123000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	13408000
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4943000
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6125000
CY2015Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-443000
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	739000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2458000
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	591000
CY2015Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8633000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	20297000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9206000
CY2015Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	40418000
CY2015Q3	us-gaap	Depreciation Depreciation	1900000
CY2015Q3	lnth	Tax Indemnification Income Loss TaxIndemnificationIncomeLoss	439000
CY2015Q3	lnth	Incremental Common Shares Attributable To Restricted Stock Awards IncrementalCommonSharesAttributableToRestrictedStockAwards	289911	shares

Files In Submission

Name	View Source	Status
0001193125-15-366322-index-headers.html	Edgar Link	pending
0001193125-15-366322-index.html	Edgar Link	pending
0001193125-15-366322.txt	Edgar Link	pending
0001193125-15-366322-xbrl.zip	Edgar Link	pending
d19736d10q.htm	Edgar Link	pending
d19736dex101.htm	Edgar Link	pending
d19736dex102.htm	Edgar Link	pending
d19736dex311.htm	Edgar Link	pending
d19736dex312.htm	Edgar Link	pending
d19736dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lnth-20150930.xml	Edgar Link	completed
lnth-20150930.xsd	Edgar Link	pending
lnth-20150930_cal.xml	Edgar Link	unprocessable
lnth-20150930_def.xml	Edgar Link	unprocessable
lnth-20150930_lab.xml	Edgar Link	unprocessable
lnth-20150930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LNTH
Lantheus Holdings, Inc. Stock $lnth

2015 Q4 Form 10-Q Financial Statement

#000119312515366322 Filed on November 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNTH Lantheus Holdings, Inc. Stock $lnth

2015 Q4 Form 10-Q Financial Statement

#000119312515366322 Filed on November 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNTH
Lantheus Holdings, Inc. Stock $lnth